Kurma Partners has launched BioFund 4, a new €250 million venture capital fund aimed at supporting innovation in the European pharmaceutical industry. This fund is designed to help early-stage biotech companies and startups that focus on developing innovative medicines and therapies. With a first round of funding already securing €140 million, BioFund 4 is well on its way to becoming a key player in Europe’s biotech sector.
The fund operates with a flexible approach, meaning it does not restrict its investments to any specific area of healthcare or biotechnology. This thematic agnosticism allows BioFund 4 to adapt and seize opportunities across a wide range of medical fields, from oncology and autoimmune diseases to digital health solutions and artificial intelligence. While its primary focus remains on biotechnology and health tech, the fund’s open-ended strategy gives it the agility to invest in the most promising and impactful innovations.
One of Kurma’s recent successes is Emergence, a biotech startup that was sold to Lilly for $600 million. This deal highlights the fund’s ability to support startups through to major exits, particularly in fields like rare diseases and cancer treatment. The fund is also looking to the future by exploring new areas of health technology, including artificial intelligence and digital health.
Despite its wide-ranging scope, BioFund 4 is unlikely to invest in alternative proteins, a field Kurma Partners is closely monitoring. The alternative protein market is currently undergoing a revolution in how food and nutrition are produced, driven by the need for sustainable and innovative methods of production. Kurma recognizes the significance of this shift and is actively considering how to best engage with this rapidly evolving sector. Kurma believes that success in fields like alternative proteins lies in building an industrial infrastructure that is capable of continual renewal through innovation. This long-term vision involves creating an ecosystem where companies can thrive by incorporating the latest advancements in science and technology. Although BioFund 4 is focused on the biopharmaceutical sector, Kurma’s interest in alternative proteins suggests a forward-looking approach, exploring how innovation can drive growth and development across different industries.